Overview
Acute myeloid leukemia (AML) is an aggressive blood cancer that remains a leading cause of leukemia-related deaths in adults. Medical advancements introduced targeted therapies known as tyrosine kinase inhibitors (TKIs), which focus on specific genetic mutations such as FLT3, IDH1, and IDH2. While these drugs demonstrated encouraging results in clinical trials, less has been understood about how patients fare when receiving TKIs during routine clinical practice.
Researchers evaluated real-world data from 482 adults with AML in the Flatiron Health Research Database who were treated with TKIs between 2015 and 2023. The study revealed that average survival was similar whether patients received TKIs as their initial treatment or in later lines of care, with median overall survival hovering around 12 to 13 months. Patients lived longer if they were younger, had favorable genetic risk profiles, possessed commercial insurance, or had received a stem cell transplant prior to TKI therapy.
Why this matters
This study provides critical real-world evidence showing that overall survival for AML patients on targeted therapies remains limited, regardless of the specific genetic mutation or treatment timing. These findings underscore an urgent need for more durable treatment strategies and novel combination therapies for adults facing this aggressive disease.